In this real-world cohort of Emirati patients with T2DM, SGLT2 inhibitor use was associated with sustained glycemic control, preserved renal function, and lower calculated cardiovascular risk over 5 years. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.